Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 5/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.62 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14020878 | 0.87 | HRH1 (0.65) | HRH1KCNH2 | |
| SCHEMBL10479209 | 0.84 | HRH1 (0.63) | HRH1KCNH2 | |
| SCHEMBL10568072 | 0.84 | HRH1 (0.62) | HRH1KCNH2 | |
| SCHEMBL9786914 | 0.83 | HRH1 (0.66) | HRH1KCNH2CYP2J2 | |
| SCHEMBL5694766 | 0.82 | HRH1 (0.68) | HRH1KCNH2CYP2J2 | |
| SCHEMBL16291199 | 0.82 | KCNH2 (0.67) | HRH1KCNH2CYP2J2CYP3A4 | |
| SCHEMBL6619451 | 0.82 | HRH1 (0.64) | HRH1KCNH2CYP2J2CYP3A4 | |
| SCHEMBL1108959 | 0.82 | ATM (0.66) | HRH1KCNH2 | |
| SCHEMBL28021507 | 0.81 | HTT (0.63) | HRH1KCNH2CYP2C9 | |
| SCHEMBL5728902 | 0.81 | HRH1 (0.67) | HRH1KCNH2CYP2J2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129408-B2 | Pharmaceutical composition for piperidinoalkanol compounds | AVENTISUB II INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7671071-B2 | Polymorphic Form XVI of fexofenadine hydrochloride | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-02 | — | — | US | disclosed |
| US-20100021547-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090149497-A1 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMACEUTICALS USA, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090082398-A1 | CRYSTALLINE FORMS OF FEXOFENADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-03-26 | — | — | US | disclosed |
| US-20090054486-A1 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMACEUTICALS USA, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20090012121-A1 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2009-01-08 | — | — | US | disclosed |
| US-20090012301-A1 | FEXOFENADINE CRYSTAL FORM AND PROCESSES FOR ITS PREPARATION THEREOF | TEVA PHARMACEUTICALS USA, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2007135693-A2 | INTERMEDIATES USEFUL FOR THE PREPARATION OF ANTIHISTAMINIC PIPERIDINE DERIVATIVE | IND-SWIFT LABORATORIES LIMITED (IN) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012121-A1 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE | F5, CYP3A5, CYP4F8 | HRH1 16/4885KCNH2 2128/4885CYP2J2 96/4885 |
| US-20090054486-A1 | POLYMORPHIC FORM XVI OF FEXOFENADINE HYDROCHLORIDE | UBE2V1, XDH, F5 | HRH1 67/4885KCNH2 843/4885CYP2J2 452/4885 |
| US-20090082398-A1 | CRYSTALLINE FORMS OF FEXOFENADINE HYDROCHLORIDE AND PROCESSES FOR THEIR PREPARATION | HRH2, CYP4F2, CYP4F3 | HRH1 5/4885KCNH2 544/4885CYP2J2 622/4885 |
| US-20090012301-A1 | FEXOFENADINE CRYSTAL FORM AND PROCESSES FOR ITS PREPARATION THEREOF | CYP4F3, CYP4F2, CYP2F1 | HRH1 32/4885KCNH2 299/4885CYP2J2 348/4885 |
| US-20090149497-A1 | POLYMORPHS OF FEXOFENADINE HYDROCHLORIDE | F5, CYP3A5, CYP4F8 | HRH1 20/4885KCNH2 2019/4885CYP2J2 129/4885 |
| US-20100021547-A1 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS | PKD1, CFTR, PKD2 | HRH1 572/4885KCNH2 80/4885CYP2J2 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.